Advertisement
Screener

HEPION PHARMACEUTICALS, INC. (HEPA) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

HEPION PHARMACEUTICALS, INC. Research and Development Expense

HEPION PHARMACEUTICALS, INC. (HEPA) reported Research and Development Expense of $50.92 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13

  • HEPION PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $50.92K, a 87.97% decline year-over-year.
  • HEPION PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $70.00K, a 214.82% increase year-over-year.
  • HEPION PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $0.00.
  • HEPION PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
  • HEPION PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $445.51K, a 96.24% decline from fiscal 2024.
  • HEPION PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $11.85M, a 66.76% decline from fiscal 2023.
  • HEPION PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $35.64M, a 7.12% increase from fiscal 2022.
  • HEPION PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $33.27M, a 63.12% increase from fiscal 2021.
Period endResearch and Development Expense 2 monthResearch and Development Expense 3 monthResearch and Development Expense 5 monthResearch and Development Expense 6 monthResearch and Development Expense 8 monthResearch and Development Expense 9 monthResearch and Development Expense 11 monthResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filed
2026-06-30$50.92K
10-Q · filed 2026-08-13
$120.92K
10-Q · filed 2026-08-13
$120.92K
derived: sum of 3 quarters · filed 2026-08-13
$120.92K
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$70.00K
10-Q · filed 2026-05-14
$70.00K
derived: sum of 2 quarters · filed 2026-05-14
$70.00K
derived: sum of 3 quarters · filed 2026-05-14
$493.28K
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$0.00
derived: sum of 2 quarters · filed 2026-03-12
$423.28K
derived: sum of 3 quarters · filed 2026-08-13
$445.51K
10-K · filed 2026-03-12
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$423.28K
derived: sum of 2 quarters · filed 2026-08-13
$445.51K
10-Q · filed 2025-11-12
-$146.10K
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$423.28K
10-Q · filed 2026-08-13
$445.51K
10-Q · filed 2026-08-13
-$146.10K
derived: sum of 3 quarters · filed 2026-08-13
$2.62M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$22.23K
10-Q · filed 2026-05-14
-$569.37K
derived: sum of 2 quarters · filed 2026-05-14
$2.19M
derived: sum of 3 quarters · filed 2026-05-14
$9.33M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31-$591.61K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$2.17M
derived: sum of 2 quarters · filed 2026-03-12
$9.31M
derived: sum of 3 quarters · filed 2026-03-12
$11.85M
10-K · filed 2026-03-12
2024-09-30$2.76M
10-Q · filed 2025-11-12
$9.90M
derived: sum of 2 quarters · filed 2025-11-12
$12.44M
10-Q · filed 2025-11-12
$17.88M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$7.14M
10-Q · filed 2025-08-14
$9.68M
10-Q · filed 2025-08-14
$15.12M
derived: sum of 3 quarters · filed 2025-08-14
$23.64M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$2.54M
10-Q · filed 2025-05-19
$7.98M
derived: sum of 2 quarters · filed 2025-05-19
$16.50M
derived: sum of 3 quarters · filed 2025-05-19
$28.38M
derived: sum of 4 quarters · filed 2025-05-19
2023-12-31$5.44M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-08
$13.96M
derived: sum of 2 quarters · filed 2025-04-08
$25.84M
derived: sum of 3 quarters · filed 2025-04-08
$35.64M
10-K · filed 2025-04-08
2023-09-30$8.52M
10-Q · filed 2024-11-14
$20.40M
derived: sum of 2 quarters · filed 2024-11-14
$30.20M
10-Q · filed 2024-11-14
$37.71M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$11.88M
10-Q · filed 2024-08-13
$21.68M
10-Q · filed 2024-08-13
$29.19M
derived: sum of 3 quarters · filed 2024-08-13
$34.93M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$9.80M
10-Q · filed 2024-05-21
$17.31M
derived: sum of 2 quarters · filed 2024-05-21
$23.05M
derived: sum of 3 quarters · filed 2024-05-21
$38.76M
derived: sum of 4 quarters · filed 2024-05-21
2022-12-31$7.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16
$13.26M
derived: sum of 2 quarters · filed 2024-04-16
$28.96M
derived: sum of 3 quarters · filed 2024-04-16
$33.27M
10-K · filed 2024-04-16
2022-09-30$5.74M
10-Q · filed 2023-11-20
$21.44M
derived: sum of 2 quarters · filed 2023-11-20
$25.75M
10-Q · filed 2023-11-20
$32.66M
derived: sum of 4 quarters · filed 2023-11-20
2022-06-30$15.70M
10-Q · filed 2023-08-14
$20.01M
10-Q · filed 2023-08-14
$26.92M
derived: sum of 3 quarters · filed 2023-08-14
$32.72M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31$4.31M
10-Q · filed 2023-05-12
$11.22M
derived: sum of 2 quarters · filed 2023-05-12
$17.02M
derived: sum of 3 quarters · filed 2023-05-12
$21.21M
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31$6.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-10
$12.71M
derived: sum of 2 quarters · filed 2023-04-10
$16.90M
derived: sum of 3 quarters · filed 2023-04-10
$20.40M
10-K · filed 2023-04-10
2021-09-30$5.80M
10-Q · filed 2022-11-14
$9.99M
derived: sum of 2 quarters · filed 2022-11-14
$13.49M
10-Q · filed 2022-11-14
$16.11M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$4.19M
10-Q · filed 2022-08-15
$7.68M
10-Q · filed 2022-08-15
$10.31M
derived: sum of 3 quarters · filed 2022-08-15
$14.09M
derived: sum of 4 quarters · filed 2022-08-15
2021-03-31$3.50M
10-Q · filed 2022-05-16
$6.13M
derived: sum of 2 quarters · filed 2022-05-16
$9.91M
derived: sum of 3 quarters · filed 2022-05-16
$12.86M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31$2.63M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-08
$6.41M
derived: sum of 2 quarters · filed 2022-04-08
$9.36M
derived: sum of 3 quarters · filed 2022-04-08
$12.00M
10-K · filed 2022-04-08
2020-09-30$3.78M
10-Q · filed 2021-11-15
$6.73M
derived: sum of 2 quarters · filed 2021-11-15
$9.37M
10-Q · filed 2021-11-15
$10.43M
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30$2.95M
10-Q · filed 2021-08-16
$5.59M
10-Q · filed 2021-08-16
$6.65M
derived: sum of 3 quarters · filed 2021-08-16
$7.50M
derived: sum of 4 quarters · filed 2021-08-16
2020-03-31$2.64M
10-Q · filed 2021-05-14
$3.70M
derived: sum of 2 quarters · filed 2021-05-14
$4.55M
derived: sum of 3 quarters · filed 2021-05-14
$5.30M
derived: sum of 4 quarters · filed 2021-05-14
2019-12-31$1.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31
$1.91M
derived: sum of 2 quarters · filed 2021-03-31
$2.67M
derived: sum of 3 quarters · filed 2021-03-31
$3.18M
10-K · filed 2021-03-31
2019-09-30$846.45K
10-Q · filed 2020-11-16
$1.60M
derived: sum of 2 quarters · filed 2020-11-16
$2.12M
10-Q · filed 2020-11-16
$3.16M
derived: sum of 4 quarters · filed 2020-11-16
2019-06-30$755.66K
10-Q · filed 2020-08-12
$1.27M
10-Q · filed 2020-08-12
$2.32M
derived: sum of 3 quarters · filed 2020-08-12
$4.48M
derived: sum of 4 quarters · filed 2020-08-12
2019-03-31$518.04K
10-Q · filed 2020-06-29
$1.56M
derived: sum of 2 quarters · filed 2020-06-29
$3.73M
derived: sum of 3 quarters · filed 2020-06-29
$5.85M
derived: sum of 4 quarters · filed 2020-06-29
2018-12-31$1.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-14
$3.21M
derived: sum of 2 quarters · filed 2020-05-14
$5.33M
derived: sum of 3 quarters · filed 2020-05-14
$7.59M
10-K · filed 2020-05-14
2018-09-30$2.17M
10-Q · filed 2019-11-14
$4.29M
derived: sum of 2 quarters · filed 2019-11-14
$6.55M
10-Q · filed 2019-11-14
$9.75M
derived: sum of 4 quarters · filed 2019-11-14
2018-06-30$2.12M
10-Q · filed 2019-08-14
$4.38M
10-Q · filed 2019-08-14
$7.58M
derived: sum of 3 quarters · filed 2019-08-14
$11.55M
derived: sum of 4 quarters · filed 2019-08-14
2018-03-31$2.26M
10-Q · filed 2019-05-15
$5.46M
derived: sum of 2 quarters · filed 2019-05-15
$9.42M
derived: sum of 3 quarters · filed 2019-05-15
$12.68M
derived: sum of 4 quarters · filed 2019-05-15
2017-12-31$3.20M
derived: 10-K 6 month − 10-Q 3 month · filed 2019-03-14
$7.16M
10-K · filed 2019-03-14
$10.42M
derived: sum of 3 quarters · filed 2019-03-14
$13.37M
10-K · filed 2019-03-14
2017-09-30$3.96M
10-Q · filed 2018-11-14
$7.22M
derived: sum of 2 quarters · filed 2018-11-14
$10.17M
10-Q · filed 2018-11-14
$14.49M
derived: sum of 4 quarters · filed 2018-11-14
2017-06-30$3.26M
10-Q · filed 2018-08-14
$6.20M
10-Q · filed 2018-08-14
$10.52M
derived: sum of 3 quarters · filed 2018-08-14
$13.65M
10-K · filed 2019-03-14
2017-03-31$2.94M
10-Q · filed 2018-05-15
$7.26M
derived: sum of 2 quarters · filed 2018-05-15
$10.39M
10-Q · filed 2017-04-12
$14.42M
derived: sum of 4 quarters · filed 2018-05-15
2016-12-31$4.32M
10-Q · filed 2017-02-14
$7.45M
10-KT · filed 2018-03-26
$11.47M
derived: sum of 3 quarters · filed 2018-03-26
$14.66M
derived: sum of 4 quarters · filed 2018-03-26
2016-09-30$3.13M
10-Q · filed 2017-11-14
$7.15M
derived: sum of 2 quarters · filed 2018-03-26
$10.34M
derived: sum of 3 quarters · filed 2018-03-26
$14.38M
derived: sum of 4 quarters · filed 2018-03-26
2016-06-30$4.02M
derived: 10-KT 12 month − 10-Q 9 month · filed 2018-03-26
$7.21M
derived: sum of 2 quarters · filed 2018-03-26
$11.25M
derived: sum of 3 quarters · filed 2018-03-26
$15.02M
10-KT · filed 2018-03-26
$15.02M
10-K · filed 2016-09-28
2016-03-31$3.19M
10-Q · filed 2017-04-12
$7.23M
derived: sum of 2 quarters · filed 2017-04-12
$10.99M
10-Q · filed 2017-04-12
$14.58M
derived: sum of 4 quarters · filed 2017-04-12
2015-12-31$4.04M
10-Q · filed 2017-02-14
$7.81M
10-Q · filed 2017-02-14
$11.40M
derived: sum of 3 quarters · filed 2017-02-14
$14.00M
derived: sum of 4 quarters · filed 2017-02-14
2015-09-30$3.77M
10-Q · filed 2016-11-14
$7.36M
derived: sum of 2 quarters · filed 2016-11-14
$9.96M
derived: sum of 3 quarters · filed 2016-11-14
$11.79M
derived: sum of 4 quarters · filed 2016-11-14
2015-06-30$3.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-28
$6.20M
derived: sum of 2 quarters · filed 2016-09-28
$8.02M
derived: sum of 3 quarters · filed 2016-09-28
$8.40M
10-K · filed 2016-09-28
2015-03-31$2.61M
10-Q · filed 2016-05-13
$4.43M
derived: sum of 2 quarters · filed 2016-05-13
$4.81M
10-Q · filed 2016-05-13
$5.03M
derived: sum of 4 quarters · filed 2016-05-13
2014-12-31$1.82M
10-Q · filed 2016-02-12
$2.21M
10-Q · filed 2016-02-12
$2.43M
derived: sum of 3 quarters · filed 2016-02-12
$2.50M
derived: sum of 4 quarters · filed 2016-02-12
2014-09-30$384.06K
10-Q · filed 2015-11-12
$602.95K
derived: sum of 2 quarters · filed 2015-11-12
$675.46K
derived: sum of 3 quarters · filed 2015-11-12
$684.66K
derived: sum of 4 quarters · filed 2015-11-12
2014-06-30$218.89K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-25
$291.40K
derived: sum of 2 quarters · filed 2015-09-25
$300.61K
derived: sum of 3 quarters · filed 2015-09-25
$314.25K
10-K · filed 2015-09-25
2014-03-31$72.51K
10-Q · filed 2015-05-14
$81.72K
derived: sum of 2 quarters · filed 2015-05-14
$95.35K
10-Q · filed 2015-05-14
$113.09K
10-Q · filed 2014-05-15
2013-12-31$9.21K
10-Q · filed 2015-02-12
$22.85K
10-Q · filed 2015-02-12
$40.59K
10-Q · filed 2014-02-05
2013-09-30$13.64K
10-Q · filed 2014-11-13
$31.38K
10-Q · filed 2013-11-19
2013-06-30$122.43K
10-K · filed 2014-09-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
NANOVIRICIDES, INC. (NNVC)United States$0.031B
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13
NextCure, Inc. (NXTC)United States$0.024B-0.15
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87